Alivus Life Sciences share news and announcements
NSE: ALIVUSBSE: 543322Pharmaceuticals & BiotechnologySmall Cap
Formerly Glenmark Life Sciences
Last close ₹1,250.60down ₹18.40 (1.45%)BSE ₹1,247.30
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,269.00.
52-week range of traded prices to 23 Oct 2026
₹819.00Low, 22 Jan 2026₹1,493.80High, 31 Aug 2026
- Next results date: the board meets on 29 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹15,354 Cr502nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 30 Jul 2026
- 25.5
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 14 May 2026
- 4.6
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.40%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 30 Jul 2026
- 19.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 30 Jul 2026
- 22.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 14 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 87,23655.9% delivered
Alivus Life Sciences share news and announcements
279 announcements, routine notices left out, newest first. Page 2 of 6.
Dec 2025
18 Dec · Analysts
15 Dec · Analysts
11 Dec · Analysts
3 Dec · Analysts
1 Dec · Analysts
Nov 2025
27 Nov · Analysts
14 Nov · Analysts
Oct 2025
30 Oct · Analysts
Sep 2025
16 Sep · Rating
8 Sep · General Updates
3 Sep · Address Change
Aug 2025
26 Aug · Analysts
21 Aug · Analysts
12 Aug · General Updates
4 Aug · Analysts
2 Aug · Analysts
Jul 2025
24 Jul · Analysts
Jun 2025
23 Jun · Meeting
9 Jun · Analysts
May 2025
30 May · Analysts
20 May · Analysts
15 May · Management
8 May · Analysts
Apr 2025
30 Apr · Disclosure